Removal of the DATA Waiver Requirement for Practitioners !!

Posted 2 months ago by Keith Chamberland


RIDOH Provider Advisory

The following provider advisory was sent to Rhode Island prescribers of controlled substances. The advisory raises awareness about the removal of the DATA Waiver for practitioners prescribing buprenorphine. You are encouraged to review this communication and share within your network.

January 19, 2023

Removal of the DATA Waiver Requirement for Practitioners

The Consolidated Appropriations Act of 2023 has eliminated the federal requirement for practitioners to have a DATA waiver to prescribe medications, like buprenorphine, for the treatment of opioid use disorder (OUD). The US Department of Justice Drug Enforcement Administration (DEA) and the Substance Abuse Mental Health Services Administration (SAMHSA) recently announced these important changes to the DATA waiver program.

  • Practitioners may now prescribe buprenorphine for OUD in their practice if permitted by applicable State law. 
  • All prescriptions will only require a standard DEA registration number.
  • In addition, there will no longer be limits on the number of patients a prescriber may treat for OUD with buprenorphine. 
  • New training requirements for all prescribers will go into effect on June 21, 2023. The DEA and SAMHSA are currently working to provide further guidance. 

Several local and national resources are available to support healthcare providers who wish to expand buprenorphine prescribing practices. These resources include:  

For more information, please contact Dr. Collette Onyejekwe, Rhode Island Prescription Drug Monitoring Program.
Rhode Island healthcare providers

Unsubscribe from this list | Forward to a friend | Update your profile

Copyright (C) 2023 Rhode Island Department of Health. All rights reserved.